About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Docs on Twitter


Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Monsanto Co. v. McFarling (Fed. Cir. 2007) | Main | USPTO NEWS: Patent Office to Hold Quarterly Biotechnology/Chemical/Pharmaceutical Customer Partnership Meeting »

June 05, 2007

Amgen to Acquire Ilypsa

    By Sherri Oslick --

AmgenOn Monday, Amgen Inc. of Thousand Oaks, CA announced that it would acquire drug company Ilypsa, Inc. of Santa Clara, CA for $420 million cash.  Ilypsa, formerly Symyx Therapeutics, is a private company developing non-absorbed, GI based drugs for phosphate, potassium, and sodium management in patients with chronic kidney disease.  Following acquisition, Ilypsa will be a wholly owned subsidiary of Amgen.

Ilypsa_cmyk_small1 Ilypsa has fifteen product candidates in various stages of development.  Its lead candidate, ILY101, a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients on hemodialysis, is currently in Phase II trials.  Ilypsa's patent portfolio includes at least six published U.S. patent applications.

For additional information regarding the acquisition, please see:

Posted at 01:46 PM in Licensing |

Comments

The comments to this entry are closed.

September 2023

Sun Mon Tue Wed Thu Fri Sat
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Categories

Archives

More...